Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
Clin Case Rep ; 7(9): 1829-1830, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31534770

RESUMO

Pure erythroid leukemia is an aggressive form of acute leukemia, presenting with pancytopenia. It is defined as a neoplasm of erythroid lineage without a significant myeloblastic component, representing >80% of marrow, with 30% or more proerythroblasts. The disease has a rapid clinical course with median survival of only 3 months.

4.
Blood Coagul Fibrinolysis ; 30(8): 419-422, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31483321

RESUMO

: Primary myelofibrosis (PMF) is a clonal hematopoietic stem cell disorder characterized by fibrosis of the marrow cavity, marked megakaryocyte atypia and progressive cytopenias. Although thrombosis predominates, bleeding is the primary manifestation in up to 20% of patients and may be life-threatening. In this report, we document restoration of megakaryocyte and platelet structure and function in PMF after allogeneic hematopoietic cell transplantation (HCT). A 59-year-old man presented with recurrent episodes of postoperative bleeding preceding a diagnosis of primary myelofibrosis (PMF). Platelet aggregation and secretion studies showed abnormal responses to all agonists tested (epinephrine, ADP, arachidonic acid, U46619, collagen, ristocetin) despite the presence of thrombocytosis. After an allogeneic HCT, platelet morphology and function studies were all normal. The pathophysiology of platelet dysfunction in myeloid neoplasia is not well understood but, as highlighted in our report, restoration of platelet function by HCT supports a clonal process involving an early hematopoietic progenitor cell.


Assuntos
Transtornos Plaquetários/etiologia , Transplante de Células-Tronco Hematopoéticas , Mielofibrose Primária/etiologia , Recuperação de Função Fisiológica , Transtornos Plaquetários/terapia , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Hemorragia/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária/efeitos dos fármacos , Mielofibrose Primária/complicações , Mielofibrose Primária/terapia , Trombocitose , Transplante Homólogo , Resultado do Tratamento
5.
Sci Rep ; 9(1): 3358, 2019 03 04.
Artigo em Inglês | MEDLINE | ID: mdl-30833650

RESUMO

Classification of histologic patterns in lung adenocarcinoma is critical for determining tumor grade and treatment for patients. However, this task is often challenging due to the heterogeneous nature of lung adenocarcinoma and the subjective criteria for evaluation. In this study, we propose a deep learning model that automatically classifies the histologic patterns of lung adenocarcinoma on surgical resection slides. Our model uses a convolutional neural network to identify regions of neoplastic cells, then aggregates those classifications to infer predominant and minor histologic patterns for any given whole-slide image. We evaluated our model on an independent set of 143 whole-slide images. It achieved a kappa score of 0.525 and an agreement of 66.6% with three pathologists for classifying the predominant patterns, slightly higher than the inter-pathologist kappa score of 0.485 and agreement of 62.7% on this test set. All evaluation metrics for our model and the three pathologists were within 95% confidence intervals of agreement. If confirmed in clinical practice, our model can assist pathologists in improving classification of lung adenocarcinoma patterns by automatically pre-screening and highlighting cancerous regions prior to review. Our approach can be generalized to any whole-slide image classification task, and code is made publicly available at https://github.com/BMIRDS/deepslide .


Assuntos
Adenocarcinoma de Pulmão/classificação , Adenocarcinoma de Pulmão/patologia , Neoplasias Pulmonares/patologia , Redes Neurais de Computação , Adenocarcinoma de Pulmão/cirurgia , Automação , Aprendizado Profundo , Técnicas Histológicas/métodos , Humanos , Neoplasias Pulmonares/classificação , Patologistas
6.
Int J Surg Pathol ; 26(5): 428-431, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29569516

RESUMO

Intravascular large B-cell lymphoma (IVLBCL) is a subtype of diffuse large B-cell lymphoma, where the neoplastic lymphoid proliferation resides predominantly within the lumens of blood vessels but with no or few circulating neoplastic cells in the peripheral circulation. Focal or subtle involvement in some cases can cause the diagnosis to be misinterpreted or even overlooked, delaying the initiation of appropriate treatment. Our report focuses on a 78-year-old woman with a progressively enlarging thyroid mass, verified by ultrasound. She underwent a hemithyroidectomy, and microscopic evaluation demonstrated nodular thyroid parenchyma with atypical large cells in an intravascular distribution pattern identified on high magnification. Thorough evaluation showed that the large intravascular cells were positive CD20, PAX-5, and Ki-67 by immunoperoxidase staining, which lead to the diagnosis of IVLBCL. This case emphasizes the subtle appearance of IVLBCL, which may be missed on low-power light microscopy, and the need for careful evaluation of thyroid resection specimens.


Assuntos
Linfoma Difuso de Grandes Células B/patologia , Nódulo da Glândula Tireoide/patologia , Neoplasias Vasculares/patologia , Idoso , Anticorpos Monoclonais Murinos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biópsia por Agulha Fina , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Feminino , Humanos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Prednisona/uso terapêutico , Rituximab , Fatores de Tempo , Resultado do Tratamento , Neoplasias Vasculares/tratamento farmacológico , Vincristina/uso terapêutico
7.
Chest ; 152(6): e133-e138, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-29223272

RESUMO

A 49-year-old woman with a medical history of essential hypertension presented to the ED with severe pain in the left superior chest and dull aching pain in the upper flank, lasting for the last 2 days.


Assuntos
Ganglioneuroma/diagnóstico , Neoplasias do Mediastino/diagnóstico , Toracoscopia/métodos , Diagnóstico Diferencial , Feminino , Ganglioneuroma/cirurgia , Humanos , Imageamento por Ressonância Magnética , Neoplasias do Mediastino/cirurgia , Pessoa de Meia-Idade , Radiografia Torácica , Procedimentos Cirúrgicos Robóticos/métodos , Tomografia Computadorizada por Raios X
8.
Transfusion ; 57(12): 2937-2941, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28905389

RESUMO

BACKGROUND: Drug-induced immune hemolytic anemia (DIIHA) and drug-induced immune thrombocytopenia (DIIT) are rare but dangerous complications of pharmacotherapy that may be underrecognized in hematopoietic stem cell transplant (HSCT) patients due to overlap of signs and symptoms with those of more common disease processes. CASE REPORT: A 61-year-old woman with NK-cell deficiency and GATA-2-associated myelodysplastic syndrome, status post-recent allogeneic HSCT (Day +58), presented with 3 days of acute-onset severe back pain, muscle cramps, and increasingly dark urine. She was found to be anemic, thrombocytopenic, and in acute renal failure. On admission, the direct antiglobulin test was positive for complement (C3) only. After careful review of her medication list, the possibility of DIIHA was raised. She had started taking trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jiroveci pneumonia prophylaxis 24 days prior on a weekend dose schedule. Serologic tests on peripheral blood samples were performed using standard methods. Drug studies were performed at an immunohematology reference laboratory. RESULTS: The patient's serum showed hemolysis of donor red blood cells in the presence of TMP-SMX and also TMP-SMX-induced platelet antibodies. The patient was treated with transfusions, hemodialysis, and immunosuppressive agents. Her clinical condition improved and she was discharged after 8 days in stable condition. CONCLUSION: This case describes the first reported concurrent DIIHA and DIIT due to TMP-SMX-induced antibodies in an HSCT patient. DIIHA and DIIT can present a diagnostic challenge in the setting of intermittent medication dosing.


Assuntos
Anemia Hemolítica/induzido quimicamente , Trombocitopenia/induzido quimicamente , Combinação Trimetoprima e Sulfametoxazol/toxicidade , Anemia Hemolítica/complicações , Anemia Hemolítica/diagnóstico , Anemia Hemolítica/terapia , Transfusão de Sangue , Feminino , Humanos , Imunossupressores/uso terapêutico , Pessoa de Meia-Idade , Diálise Renal , Trombocitopenia/complicações , Trombocitopenia/diagnóstico , Trombocitopenia/terapia , Reação Transfusional , Resultado do Tratamento , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...